Document and Entity Information - shares |
9 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 |
Nov. 10, 2017 |
|||||||||||||
| Document And Entity Information [Abstract] | ||||||||||||||
| Entity Registrant Name | Akers Biosciences, Inc. | |||||||||||||
| Entity Central Index Key | 0001321834 | |||||||||||||
| Document Type | 10-Q/A | |||||||||||||
| Document Period End Date | Sep. 30, 2017 | |||||||||||||
| Amendment Flag | true | |||||||||||||
| Amendment Description |
This Amendment No. 1 on Form 10-Q/A (this “Form 10-Q/A") amends and restates certain items noted below in the Quarterly Report on Form 10-Q of Akers Biosciences, Inc. (the “Company”) for the quarterly period ended September 30, 2017, as originally filed with the Securities and Exchange Commission on November 14, 2017 (the “Original Filing”). This Form 10-Q/A amends the Original Filing to reflect the correction of an error in the previously reported quarterly period ended September 30, 2017 financial statements related to the Company’s revenue and expense recognition. See Note 2 to the Condensed Consolidated Financial Statements included in Part I, Item 1, for additional information and a reconciliation of the previously reported amounts to the restated amounts.
For the convenience of the reader, this Form 10-Q/A sets forth the Original Filing, as amended, in its entirety; however, this Form 10-Q/A amends and restates only the following financial statements and disclosures that were impacted from the correction of the error:
The Company’s Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date of this filing in connection with this Form 10-Q/A (Exhibits 31.1, 31.2, 32.1 and 32.2), and the Company has provided its condensed consolidated financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibit 101.
Except as described above, no other changes have been made to the Original Filing. This Form 10-Q/A speaks as of the date of the Original Filing and does not reflect events that may have occurred after the date of the Original Filing, or modify or update any disclosures that may have been affected by subsequent events.
The Company is also concurrently filing an amended Quarterly Report on Form 10-Q for the three and six months ended June 30, 2017 and 2016 and an amended Annual Report for the years ended December 31, 2017 and 2016 to restate those previously issued financial statements. |
|||||||||||||
| Current Fiscal Year End Date | --12-31 | |||||||||||||
| Entity Filer Category | Smaller Reporting Company | |||||||||||||
| Entity Common Stock, Shares Outstanding | 9,920,552 | |||||||||||||
| Trading symbol | AKER | |||||||||||||
| Document Fiscal Period Focus | Q3 | |||||||||||||
| Document Fiscal Year Focus | 2017 |